GlobeImmune-Gilead Immunotherapy Fails to Perform in Hepatitis B

The first of two phase 2 trials testing GlobeImmune’s (GBIM) GS-4774, an immunotherapy directed towards Hepatitis B and partnered with Gilead Sciences (GILD), has failed. The stock is down 50% in the wake of this news.